BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 38266179)

  • 21. Targeted Genomic Sequencing Reveals Novel
    Jung YY; Woo HY; Kim HS
    Anticancer Res; 2019 Jun; 39(6):2883-2889. PubMed ID: 31177126
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased expression of neurotensin in high grade serous ovarian carcinoma with evidence of serous tubal intraepithelial carcinoma.
    Norris EJ; Zhang Q; Jones WD; DeStephanis D; Sutker AP; Livasy CA; Ganapathi RN; Tait DL; Ganapathi MK
    J Pathol; 2019 Jul; 248(3):352-362. PubMed ID: 30883751
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HNF-1β in ovarian carcinomas with serous and clear cell change.
    DeLair D; Han G; Irving JA; Leung S; Ewanowich CA; Longacre TA; Gilks CB; Soslow RA
    Int J Gynecol Pathol; 2013 Nov; 32(6):541-6. PubMed ID: 24071869
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Primary and recurrent ovarian high-grade serous carcinomas display similar microRNA expression patterns relative to those of normal ovarian tissue.
    Nam EJ; Kim S; Lee TS; Kim HJ; Lee JY; Kim SW; Kim JH; Kim YT
    Oncotarget; 2016 Oct; 7(43):70524-70534. PubMed ID: 27655640
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy.
    Li M; Li H; Liu F; Bi R; Tu X; Chen L; Ye S; Cheng X
    J Ovarian Res; 2017 Feb; 10(1):9. PubMed ID: 28187748
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinicopathological study of SET subtype of ovarian high-grade serous carcinoma].
    Sun YW; Shen DH; Cui SS; He HJ; Zhang XL; Wang W; Liu CR
    Zhonghua Fu Chan Ke Za Zhi; 2019 Sep; 54(9):595-600. PubMed ID: 31550775
    [No Abstract]   [Full Text] [Related]  

  • 27. Anterior gradient protein 2 (AGR2) is an independent prognostic factor in ovarian high-grade serous carcinoma.
    Darb-Esfahani S; Fritzsche F; Kristiansen G; Weichert W; Sehouli J; Braicu I; Dietel M; Denkert C
    Virchows Arch; 2012 Aug; 461(2):109-16. PubMed ID: 22752467
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma.
    Morales-Vásquez F; Pedernera E; Reynaga-Obregón J; López-Basave HN; Gómora MJ; Carlón E; Cárdenas S; Silva-Ayala R; Almaraz M; Méndez C
    J Ovarian Res; 2016 Jul; 9(1):41. PubMed ID: 27388275
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The prognostic value of perioperative, pre-systemic therapy CA125 levels in patients with high-grade serous ovarian cancer.
    May T; Stewart JM; Bernardini MQ; Ferguson SE; Laframboise S; Jiang H; Rosen B
    Int J Gynaecol Obstet; 2018 Feb; 140(2):247-252. PubMed ID: 29095487
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer.
    Koti M; Siu A; Clément I; Bidarimath M; Turashvili G; Edwards A; Rahimi K; Mes-Masson AM; Squire JA
    Br J Cancer; 2015 Mar; 112(7):1215-22. PubMed ID: 25826225
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nicotinamide N-methyltransferase overexpression may be associated with poor prognosis in ovarian cancer.
    Harmankaya İ; Akar S; Uğraş S; Güler AH; Ezveci H; Aydoğdu M; Çelik Ç
    J Obstet Gynaecol; 2021 Feb; 41(2):248-253. PubMed ID: 32285726
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glycoproteomics-based signatures for tumor subtyping and clinical outcome prediction of high-grade serous ovarian cancer.
    Pan J; Hu Y; Sun S; Chen L; Schnaubelt M; Clark D; Ao M; Zhang Z; Chan D; Qian J; Zhang H
    Nat Commun; 2020 Dec; 11(1):6139. PubMed ID: 33262351
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Single-cell RNA-sequencing analysis reveals divergent transcriptome events between platinum-sensitive and platinum-resistant high-grade serous ovarian carcinoma.
    Wang Z; Yang L; Su X; Wu X; Su R
    J Gene Med; 2023 Oct; 25(10):e3504. PubMed ID: 36994597
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Keratin 7 and E-Cadherin Signature Is Highly Predictive of Tubo-Ovarian High-Grade Serous Carcinoma Prognosis.
    Communal L; Roy N; Cahuzac M; Rahimi K; Köbel M; Provencher DM; Mes-Masson AM
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34070214
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Morphologic features of fallopian tubal epithelium in pelvic high-grade serous carcinoma].
    Zhao RJ; Wang YY; Li Z; Wu KY; Kong LF; Zheng WX
    Zhonghua Bing Li Xue Za Zhi; 2017 Aug; 46(8):542-547. PubMed ID: 28810294
    [No Abstract]   [Full Text] [Related]  

  • 36. Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study.
    Vang R; Levine DA; Soslow RA; Zaloudek C; Shih IeM; Kurman RJ
    Int J Gynecol Pathol; 2016 Jan; 35(1):48-55. PubMed ID: 26166714
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic marker.
    Vilming Elgaaen B; Olstad OK; Haug KB; Brusletto B; Sandvik L; Staff AC; Gautvik KM; Davidson B
    BMC Cancer; 2014 Feb; 14():80. PubMed ID: 24512620
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Defining the molecular evolution of extrauterine high grade serous carcinoma.
    Beirne JP; McArt DG; Roddy A; McDermott C; Ferris J; Buckley NE; Coulter P; McCabe N; Eddie SL; Dunne PD; O'Reilly P; Gilmore A; Feeney L; Ewing DL; Drapkin RI; Salto-Tellez M; Kennedy RD; Harley IJG; McCluggage WG; Mullan PB
    Gynecol Oncol; 2019 Nov; 155(2):305-317. PubMed ID: 31493898
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tissue and plasma levels of galectins in patients with high grade serous ovarian carcinoma as new predictive biomarkers.
    Labrie M; De Araujo LOF; Communal L; Mes-Masson AM; St-Pierre Y
    Sci Rep; 2017 Oct; 7(1):13244. PubMed ID: 29038585
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Distinct preoperative clinical features predict four histopathological subtypes of high-grade serous carcinoma of the ovary, fallopian tube, and peritoneum.
    Ohsuga T; Yamaguchi K; Kido A; Murakami R; Abiko K; Hamanishi J; Kondoh E; Baba T; Konishi I; Matsumura N
    BMC Cancer; 2017 Aug; 17(1):580. PubMed ID: 28851311
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.